Company intelligence / Profile preview

Invictus Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

Invectys has a CAR-T Cell Therapy (IVS-3001) with FDA Fast Track designation for Renal Cell Carcinoma and has initiated a Phase 1/2a clinical trial in solid tumors. Invictus Oncology is a clinical-stage biotechnology company developing platinum chemotherapies for various cancers.

Therapeutic areas: Oncology
Modalities: NutraceuticalsImmunotherapyCAR-T Cell TherapyPlatinum chemotherapies
Industry: Biotech

Drug pipeline

1 asset

INV-102

Pre-clinical

Indications: Ocular sulfur mustard gas injury, Viral infections, Pulmonary infections, Pulmonary injuries

Partnerships

India Innovation Research Center

Beyond the preview

Go deeper on Invictus Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Invictus Therapeutics.

Explore the full profile